{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:44:14Z","timestamp":1790801054119,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejps.2020.105631","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T10:43:45Z","timestamp":1603622625000},"page":"105631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Yan","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105631_bib0001","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2020.105631_bib0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ejps.2020.105631_bib0003","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejps.2020.105631_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"10.1016\/j.ejps.2020.105631_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ejps.2020.105631_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ejps.2020.105631_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa107","article-title":"Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza","author":"Abraham","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.ejps.2020.105631_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200746010-00005","article-title":"Lopinavir\/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis","volume":"46","author":"Molt\u00f3","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105631_bib0009","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5414\/CP201843","article-title":"Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers","volume":"51","author":"Sun","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ejps.2020.105631_bib0010","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.02282-12","article-title":"Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans","volume":"57","author":"Deng","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ejps.2020.105631_bib0011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial","volume":"11","author":"Tashima","year":"2014","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ejps.2020.105631_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejps.2020.105631_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action","volume":"49","author":"Bazzoli","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejps.2020.105631_bib0014","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2015.08.015","article-title":"Ebola virus dynamics in mice treated with favipiravir","volume":"123","author":"Madelain","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejps.2020.105631_bib0015","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.ejps.2020.105631_bib0016","doi-asserted-by":"crossref","unstructured":"Chen, C., Huang, J.Y., Yin, P., 2020. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medrxiv. 10.1101\/2020.03.17.20037432.","DOI":"10.1101\/2020.03.17.20037432"},{"key":"10.1016\/j.ejps.2020.105631_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of Favipiravir in Critically ill Patients with COVID-19","author":"Irie","year":"2020","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.ejps.2020.105631_bib0018","doi-asserted-by":"crossref","unstructured":"Lou, Y., Liu, L., Yao, H.P., et\u00a0al. 2020. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. medrxiv. 10.1101\/2020.04.29.20085761.","DOI":"10.1101\/2020.04.29.20085761"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030419X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030419X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:11:27Z","timestamp":1769886687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872030419X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"alternative-id":["S092809872030419X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105631","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.29.20085761","asserted-by":"object"}]},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105631"}}